Sirui Tan Jing Yu Qiyue Huang Nan Zhou Xianze Xiong Hongfeng Gou
10.3389/fphar.2022.1037646
Front Pharmacol
2022 Nov 28;13:1037646.
cholangiocarcinoma immunotherapy nab-paclitaxel pembrolizumab tumor microenvironment
CC BY
https://pubmed.ncbi.nlm.nih.gov/36518664/
Case Reports
PMC9742598
36518664
Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
2022